A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’broad
BAT-90 · Horizon Europe grant · 2024-04-01–2025-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
BetaGlue is developing an innovative ""radiotherapy from within"", personalized and cost-effective anti-tumoural platform technology called BAT-90. BAT-90 maximises the therapeutic index of loco-regional treatment by eliminating off-target radiation dose in a simple and easy to use product. The product aims to provide a radiotherapeutic treatment option for a range of solid tumour types including: unresectable hepatocellular carcinoma (HCC) and locally advanced and borderline resectable pancreatic cancer (PDAC) patients, where in the first-line setting, there exists a major unmet clinical need. Through the percutaneous administration of BAT-90 under radiological guidance (usually ultrasound) BAT-90 overcomes the accessibility and off-target side effect limitations of external beam radiotherapy, forms of brachytherapy, proton beam radiotherapy trans-arterial radio-embolisation and microwave ablation. BAT-90 has already demonstrated safety and preliminary effectiveness in first-in-human clinical studies.""
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| BETAGLUE THERAPEUTICS SPA | IT | coordinator | €2,499,999 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.